Dr. Aboulafia on Targeted Therapy in Tenosynovial Giant Cell Tumor


Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

Albert J. Aboulafia, MD, medical director of the Weinberg Cancer Institute at MedStar Franklin Square Medical Center, discusses targeted therapy options in tenosynovial giant cell tumor (TGCT).

Currently in the TGCT space, there are few precision medicine initiatives, says Aboulafia. A phase I trial is examining the use of targeted therapies within TGCT, and could provide some insight into this heterogenous disease.

Soft tissue sarcomas, including synovial sarcoma, myxoid liposarcoma, and alveolar rhabdomyosarcoma, have translocations or molecular rearrangements, says Aboulafia. A small number of patients have targetable mutations. The National Cancer Institute-MATCH trial shows that if an NTRK fusion, for example, is detected with molecular profiling, the patient can be treated with NTRK-targeted therapy.

Rather than the sarcoma or tumor type, it is the mutation that is specifically targeted, Aboulafia concludes.

Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.